Pacira BioSciences' Cash & Equivalents fell 3999.59% to $147.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.6 million, marking a year-over-year decrease of 3999.59%. This contributed to the annual value of $276.8 million for FY2024, which is 8054.64% up from last year.
According to the latest figures from Q3 2025, Pacira BioSciences' Cash & Equivalents is $147.6 million, which was down 3999.59% from $300.5 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Cash & Equivalents registered a high of $585.6 million during Q4 2021, and its lowest value of $35.5 million during Q1 2023.
Over the past 5 years, Pacira BioSciences' median Cash & Equivalents value was $147.6 million (recorded in 2025), while the average stood at $185.0 million.
Per our database at Business Quant, Pacira BioSciences' Cash & Equivalents surged by 48582.99% in 2021 and then crashed by 8432.42% in 2023.
Over the past 5 years, Pacira BioSciences' Cash & Equivalents (Quarter) stood at $585.6 million in 2021, then crashed by 82.22% to $104.1 million in 2022, then soared by 47.21% to $153.3 million in 2023, then soared by 80.55% to $276.8 million in 2024, then crashed by 46.68% to $147.6 million in 2025.
Its Cash & Equivalents stands at $147.6 million for Q3 2025, versus $300.5 million for Q2 2025 and $283.6 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value